Base on this, adiponectin could be considered as a biomarker of those hepatic pathologies, such as NAFLD, NASH, and hepatic tumor, that have been shown to be associated with hypoadiponectinemia. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.